Multi-Functional Norrin Is a Ligand for the LGR4 Receptor
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Edinburgh Research Explorer
Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners. -
G Protein‐Coupled Receptors
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. -
Wnt/Rspondin/Β-Catenin Signals Control Axonal Sorting and Lineage Progression in Schwann Cell Development
Wnt/Rspondin/β-catenin signals control axonal sorting and lineage progression in Schwann cell development Tamara Grigoryana, Simone Steina, Jingjing Qia, Hagen Wendeb, Alistair N. Garrattc, Klaus-Armin Naved, Carmen Birchmeierb, and Walter Birchmeiera,1 aCancer Research Program and bNeuroscience Program, Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; cCenter for Anatomy, Charité University Hospital, 10117 Berlin, Germany; and dDepartment of Neurogenetics, Max Planck Institute for Experimental Medicine, 37075 Göttingen, Germany Edited by Thomas C. Südhof, Stanford University School of Medicine, Stanford, CA, and approved September 26, 2013 (received for review June 2, 2013) During late Schwann cell development, immature Schwann cells organs (24–27). A role of Rspondins and Lgr4–6 receptors in SC segregate large axons from bundles, a process called “axonal ra- development has not been studied. dial sorting.” Here we demonstrate that canonical Wnt signals play Here we define a temporal window of Wnt/β-catenin activity a critical role in radial sorting and assign a role to Wnt and Rspon- and its role in SC lineage progression using mouse genetics and din ligands in this process. Mice carrying β-catenin loss-of-function cell culture techniques. Conditional loss-of-function (LOF) and mutations show a delay in axonal sorting; conversely, gain-of-function gain-of-function (GOF) mutations of β-catenin in mouse SCs mutations result in accelerated sorting. Sorting deficits are accom- produce converse phenotypes: a delay and an acceleration of panied by abnormal process extension, differentiation, and aber- axonal sorting, respectively. Using cultured primary SCs and rant cell cycle exit of the Schwann cells. -
G Protein-Coupled Receptors
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A. (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology, 174, S17-S129. https://doi.org/10.1111/bph.13878 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13878 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13878 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors Stephen PH Alexander1, Arthur Christopoulos2, Anthony P Davenport3, Eamonn Kelly4, Neil V Marrion4, John A Peters5, Elena Faccenda6, Simon D Harding6,AdamJPawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6 and CGTP Collaborators 1 School of Life Sciences, -
MRGPRX4 Is a Novel Bile Acid Receptor in Cholestatic Itch Huasheng Yu1,2,3, Tianjun Zhao1,2,3, Simin Liu1, Qinxue Wu4, Omar
bioRxiv preprint doi: https://doi.org/10.1101/633446; this version posted May 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 MRGPRX4 is a novel bile acid receptor in cholestatic itch 2 Huasheng Yu1,2,3, Tianjun Zhao1,2,3, Simin Liu1, Qinxue Wu4, Omar Johnson4, Zhaofa 3 Wu1,2, Zihao Zhuang1, Yaocheng Shi5, Renxi He1,2, Yong Yang6, Jianjun Sun7, 4 Xiaoqun Wang8, Haifeng Xu9, Zheng Zeng10, Xiaoguang Lei3,5, Wenqin Luo4*, Yulong 5 Li1,2,3* 6 7 1State Key Laboratory of Membrane Biology, Peking University School of Life 8 Sciences, Beijing 100871, China 9 2PKU-IDG/McGovern Institute for Brain Research, Beijing 100871, China 10 3Peking-Tsinghua Center for Life Sciences, Beijing 100871, China 11 4Department of Neuroscience, Perelman School of Medicine, University of 12 Pennsylvania, Philadelphia, PA 19104, USA 13 5Department of Chemical Biology, College of Chemistry and Molecular Engineering, 14 Peking University, Beijing 100871, China 15 6Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory 16 of Molecular Diagnosis on Dermatoses, Beijing 100034, China 17 7Department of Neurosurgery, Peking University Third Hospital, Peking University, 18 Beijing, 100191, China 19 8State Key Laboratory of Brain and Cognitive Science, CAS Center for Excellence in 20 Brain Science and Intelligence Technology (Shanghai), Institute of Biophysics, 21 Chinese Academy of Sciences, Beijing, 100101, China 22 9Department of Liver Surgery, Peking Union Medical College Hospital, Chinese bioRxiv preprint doi: https://doi.org/10.1101/633446; this version posted May 9, 2019. -
GPR48 Increases Mineralocorticoid Receptor Gene Expression
BASIC RESEARCH www.jasn.org GPR48 Increases Mineralocorticoid Receptor Gene Expression † † Jiqiu Wang,* Xiaoying Li,* Yingying Ke,* Yan Lu,* Feng Wang, Nengguang Fan,* ‡ Haiyan Sun,* Huijie Zhang,* Ruixin Liu,* Jun Yang,* Lei Ye,* Mingyao Liu, and † Guang Ning* *Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrinology and Metabolism, Shanghai Key Laboratory for Endocrine Tumors and E-Institute of Shanghai Universities, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; †Laboratory for Endocrine and Metabolic Diseases, Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences, Shanghai, China; and ‡Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas ABSTRACT Aldosterone and the mineralocorticoid receptor (MR) are critical to the maintenance of electrolyte and BP homeostasis. Mutations in the MR cause aldosterone resistance known as pseudohypoaldosteronism type 1 (PHA1); however, some cases consistent with PHA1 do not exhibit known gene mutations, suggesting the possibility of alternative genetic variants. We observed that G protein–coupled receptor 48 (Gpr48/ Lgr4) hypomorphic mutant (Gpr48m/m) mice had hyperkalemia and increased water loss and salt excretion despite elevated plasma aldosterone levels, suggesting aldosterone resistance. When we challenged the mice with a low-sodium diet, these features became more obvious; the mice also developed hyponatremia and increased renin expression and activity, resembling a mild state of PHA1. There was marked renal downregulation of MR and its downstream targets (e.g., the a-subunit of the amiloride-sensitive epithelial sodium channel), which could provide a mechanism for the aldosterone resistance. We identified a non- canonical cAMP-responsive element located in the MR promoter and demonstrated that GPR48 upregulates MR expression via the cAMP/protein kinase A pathway in vitro. -
The Role of Gpcrs in Bone Diseases and Dysfunctions
Bone Research www.nature.com/boneres REVIEW ARTICLE OPEN The role of GPCRs in bone diseases and dysfunctions Jian Luo 1, Peng Sun1,2, Stefan Siwko3, Mingyao Liu1,3 and Jianru Xiao4 The superfamily of G protein-coupled receptors (GPCRs) contains immense structural and functional diversity and mediates a myriad of biological processes upon activation by various extracellular signals. Critical roles of GPCRs have been established in bone development, remodeling, and disease. Multiple human GPCR mutations impair bone development or metabolism, resulting in osteopathologies. Here we summarize the disease phenotypes and dysfunctions caused by GPCR gene mutations in humans as well as by deletion in animals. To date, 92 receptors (5 glutamate family, 67 rhodopsin family, 5 adhesion, 4 frizzled/taste2 family, 5 secretin family, and 6 other 7TM receptors) have been associated with bone diseases and dysfunctions (36 in humans and 72 in animals). By analyzing data from these 92 GPCRs, we found that mutation or deletion of different individual GPCRs could induce similar bone diseases or dysfunctions, and the same individual GPCR mutation or deletion could induce different bone diseases or dysfunctions in different populations or animal models. Data from human diseases or dysfunctions identified 19 genes whose mutation was associated with human BMD: 9 genes each for human height and osteoporosis; 4 genes each for human osteoarthritis (OA) and fracture risk; and 2 genes each for adolescent idiopathic scoliosis (AIS), periodontitis, osteosarcoma growth, and tooth development. Reports from gene knockout animals found 40 GPCRs whose deficiency reduced bone mass, while deficiency of 22 GPCRs increased bone mass and BMD; deficiency of 8 GPCRs reduced body length, while 5 mice had reduced femur size upon GPCR deletion. -
LGR4 in BREAST CANCER STEM CELLS a Thesis by LI ZENG
LGR4 IN BREAST CANCER STEM CELLS A Thesis by LI ZENG Submitted to the Office of Graduate and Professional Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Chair of Committee, Mingyao Liu Committee Members, Yi Li Fen Wang Yi Xu Dekai Zhang Head of Department, Van Wilson December 2014 Major Subject: Medical Sciences Copyright 2014 Li Zeng ABSTRACT Breast cancer is the most commonly diagnosed cancer among American women. G-protein coupled receptors (GPCR) comprise a huge family protein with almost 800 members. GPCRs sense molecules or other stimuli outside the cell, and activate intracellular signals. Consequently, a large proportion of modern drugs target these receptors. Lgr4 is a GPCR implicated in the development of multiple organs; in the mammary gland, it is expressed in the basal epithelial subpopulation and controls organ development by regulating stem cell activity through the wnt/β-catenin pathway. High breast tumor expression of Lgr4 correlated with a high risk of tumor relapse after chemokine therapy and an elevated risk of bone metastasis. We crossed mice bearing a gene trap cassette in the Lgr4 locus with several breast cancer mouse models such as MMTV-Wnt1 and MMTV-PyMT to study the consequences of Lgr4 expression ablation in breast cancer progression. We found that the absence of Lgr4 significantly delayed tumor progression in both MMTV-Wnt1 and MMTV-PyMT mouse models. Meanwhile, Lgr4 ablation led to diminished lung metastases in MMTV-PyMT tumors and several breast cancer cell lines. Further studies revealed that the repression of tumor progression and metastasis formation was due to a decreased cancer stem cell number in tumors with Lgr4 downregulation, as well as blocking of epithelial-mesenchymal transition. -
Introduction
GPCR Introduction G protein-coupled receptors (GPCRs) are the GPCRs Super-Family largest family of transmembrane receptors and are 375 GPCR Drug Targets, 225 with Known Ligands, 150 Orphan Targets responsible for the transduction of a diverse range of extracellular signals. The range of physiological processes mediated by GPCRs makes them one GRM7 GRM8 GLUTAMATE (15) SECRETIN GRM2 FZD7 TAS1R3 FZD2 of the most important classes of proteins for drug (15) GRM4 GRM3 TAS1R1FZD1 GLP2R GIPR GRM6 GRPC6A FRIZZED/TAS2 discovery. ADHESION GLP1R GCGR GRM5 FZD3 PTHR2 GRM1 (24) LEC1 VIPR2 PTHR1 (24) TAS1R2 FZD6 LEC2 TAS2R13 CELSR2PACAP FZD8 The study of GPCRs may involve ligand binding, G CRHR2 FZD5 TAS2R16 TAS2R14 CALCRL LEC3 VIPR1 CRHR1 CASR GABBR2 FZD10 TAS2R1 TAS2R10 EMR3EMR2 CELSR3 BAI2 CALCR FZD4 TAS2R5 TAS2R3 SCTR FZD9 protein activation, internalization, and downstream ETL BAI3 GPR60 TAS2R9 CELSR1 GHRHR GABBR1 GPR59 TAS2R8 TAS2R4 TAS2R7 EMR1 BAI1 SMOH CXCR3 second messenger events. Each step of the CXCR5 CCR11 CXCR2 CD97 SSTR1 SSTR3 CCR10 CCR6 SSTR5 CXCR1 GPR111 CXCR6 pathway offers an opportunity to exploit the full SSTR2 CCR9 GPR115 SSTR4 CCR7 GPR116 GPR112 GPR8 CCRL2 GPR113 GPR7 CXC3R1CCR8 therapeutic potential of targeting GPCRs. GPR110 CCR4 HE6 NTSR2 CCR1 TM7XN1 GPR114 NMU1R GPR54 GALR1 CCBP2 GHSR GALR2 RDC1 CCR3 GPR97 NPY1R XCR1 PPYR1 NMU2R MTLR MCHR1 GALR3 ADMR NPY2R AGTR1 TACR3 UR2R MCHR2 AGTRL1 AGTR2 CCR5 TAC3RL PrRP γ GPR26 BDKRB2 CCR2 GRM7 GRM8 GLUTAMATE (15) TACR1 TACR2 GRP72 OR1A1 SALPR OLFACTORY GPR15 NPFF1 NPY5R OR1D2 (388) GPTH2 -
Engineering Therapeutic Antibodies Targeting G-Protein–Coupled Receptors
OPEN Experimental & Molecular Medicine (2016) 48, e207; doi:10.1038/emm.2015.105 & 2016 KSBMB. All rights reserved 2092-6413/16 www.nature.com/emm REVIEW Engineering therapeutic antibodies targeting G-protein–coupled receptors Migyeong Jo and Sang Taek Jung G-protein–coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the small exposed area of extracellular epitopes and difficulty in the preparation of GPCR antigens have delayed both the isolation of therapeutic anti-GPCR antibodies as well as studies on the structure, function and biochemical mechanisms of GPCRs. To overcome the challenges in generating highly specific anti-GPCR antibodies with enhanced efficacy and safety, various forms of antigens have been successfully designed and employed for screening with newly emerged systems based on laboratory animal immunization and high-throughput-directed evolution. Experimental & Molecular Medicine (2016) 48, e207; doi:10.1038/emm.2015.105; published online 5 February 2016 INTRODUCTION between intracellular molecules, G-proteins and arrestins.2 Since the beginning of the monoclonal antibody era led by the Because of the functional diversity of GPCRs, abnormal success of hybridoma technology in the middle of the 1970s, expression and activity of GPCRs are involved in many types a variety of platform technologies,